Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 23, 2018 08:41 ET | Source: InspireMD, Inc.

InspireMD Announces Opening of First Two CGuard™ EPS Centers of Excellence

Tel Aviv, Israel, July 23, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment...
June 18, 2018 09:42 ET | Source: InspireMD, Inc.

InspireMD’s CGuard EPS Prominently Featured at the 10th International Congress of the Polish Society for Vascular Surgery

Study results presented from 46 patients treated over two years with zero complicationsPresident of the Polish Society for Vascular Surgery presented clinical cases illustrating the advantages of...
June 11, 2018 09:53 ET | Source: InspireMD, Inc.

InspireMD’s CGuard™ MicroNet™ EPS Featured in a Live Case Transmission to the 2nd DGA Interventional Congress

Tel Aviv, Israel, June 11, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today...
May 16, 2018 08:12 ET | Source: InspireMD, Inc.

InspireMD Receives Regulatory Approval for both CGuard EPS™ and MGuard Prime™ in Ecuador

Tel Aviv, Israel, May 16, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today...
May 07, 2018 16:05 ET | Source: InspireMD, Inc.

InspireMD Reports 132% Increase in CGuard™ EPS Sales for the First Quarter of 2018

Tel Aviv, Israel, May 07, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
April 30, 2018 07:34 ET | Source: InspireMD, Inc.

InspireMD Announces Regulatory Approval and Reimbursement to Commercialize both CGuard EPS™ and MGuard™ Prime Products in Vietnam

TEL AVIV, ISRAEL, April 30, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
April 03, 2018 10:28 ET | Source: InspireMD, Inc.

InspireMD Anticipates Fifth Consecutive Quarter of Sequential Double Digit Growth; Projects 132% Increase in CGuard EPS Sales for the First Quarter of 2018; Total Quarterly Company Sales to Exceed $1 Million

TEL AVIV, Israel, April 03, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
March 05, 2018 08:07 ET | Source: InspireMD, Inc.

InspireMD Announces First Patient Treated with CGuard™ EPS in India

Patient with severe stenosis, calcification and thrombosis successfully treated with CGuard™ EPS TEL AVIV, ISRAEL, March 05, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader...
February 27, 2018 07:00 ET | Source: InspireMD, Inc.

InspireMD, Inc. Announces Pricing of Public Offering of Common Stock

TEL AVIV, ISRAEL , Feb. 27, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular...
February 22, 2018 10:16 ET | Source: InspireMD, Inc.

InspireMD Announces Exclusive Distribution, Sales and Marketing Agreement for CGuard EPS in South Korea

Solvit Medical to fund all regulatory, registration and reimbursement submissions TEL AVIV, ISRAEL, Feb. 22, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER: NSPR), a leader in...

Next Page keyboard_arrow_right